Am J Transplant, Volume 22, Suppl 3 Archives - Page 190 of 190 - ATC Abstracts

2022 American Transplant Congress
Steroid-Free Living Donor Liver Transplantation Using Rabbit Antithymocyte Globulin Induction Reduces Incidence of Acute Cellular Rejection
C. Eymard¹, S. Naik¹, J. Eason²
¹James D Eason Transplant Institute, Memphis, TN, ²University of Tennessee/Methodist Transplant Institute, Memphis, TN
*Purpose: The efficacy of steroid-free immunosuppression protocols using rabbit antithymocyte globulin (RATG) induction with tacrolimus minimization has previously been described in deceased donor liver transplantation.…
2022 American Transplant Congress
Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients
S. Anders¹, A. Freeman¹, L. Hutchinson¹, U. Kaszubski¹, M. Janusek¹, A. Hooter², D. Raymond², C. Nguyen²
¹Ochsner Medical Center, New Orleans, LA, ²Xavier University, New Orleans, LA
*Purpose: The goal of this study was to compare the safety and efficacy of a delayed valganciclovir (VGCV) dosing protocol for cytomegalovirus (CMV) prophylaxis in…
2022 American Transplant Congress
Impact of the Covid-19 Pandemic on Longitudinal Molecular Surveillance in the KOAR Registry
T. Alhamad¹, A. Malone¹, D. Mandelbrot², P. M. Anand³, H. M. Wadei⁴, G. Shekhtman⁵, N. Agrawal⁵, K. Pinney⁵, K. Qu⁵, A. Desai⁶
¹Washington University, St. Louis, MO, ²University of Wisconsin, Madison, WI, ³Medical University of South Carolina, Charleston, SC, ⁴Mayo Clinic Jacksonville, Jacksonville, FL, ⁵CareDx, Brisbane, CA, ⁶Loyola University Medical Center, Maywood, IL
*Purpose: The SARS-CoV2 pandemic increased the complexity of delivering routine clinical care and laboratory services for immunosuppressed kidney transplant (KTx) recipients. We evaluated how the…
2022 American Transplant Congress
Process Evaluation of the Ascent Study: A Hybrid Type 1 Effectiveness-Implementation Trial of a Multi-Level Intervention to Improve Dialysis Provider Knowledge of Kidney Allocation Policy Changes and Increase Kidney Transplant Waitlisting
M. A. Urbanski¹, Y. Lee¹, M. Basu¹, C. Escoffery², R. Hamoda¹, L. Plantinga³, S. O. Pastan¹, R. E. Patzer¹
¹Division of Transplantation, Emory University School of Medicine, Emory University, Atlanta, GA, ²Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA, ³Division of Geriatrics and Gerontology, Emory University School of Medicine, Emory University, Atlanta, GA
*Purpose: Kidney transplant is the optimal treatment for end-stage kidney disease, yet only a fifth of patients are on the waitlist and inequities in access…
2022 American Transplant Congress
Differences in Acceptance to the Kidney Transplant List
J. Cotton¹, K. Perry², N. Costa³, S. Niederhaus¹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Maryland Medical Center, Baltimore, MD, ³Georgetown University, Washington, DC
*Purpose: During the COVID-19 pandemic, kidney transplant (KT) evaluations shifted from in-person evaluation (IPE) to telemedicine evaluation (TME). Given differences in access to electronics and…
2022 American Transplant Congress
Association of Pre-Transplant Anti A1 IgM Antibody Titers with Survival Outcomes in A2/A2B to B Kidney Transplantation
M. Fallahzadeh, D. Shaffer, A. El Chediak, I. Feurer, S. Rega, J. L. Triozzi, S. Shawar
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The new kidney allocation system implemented in 2014 has allowed blood type B recipients to receive kidneys from A2/A2B donors. Although many centers use…
2022 American Transplant Congress
Racial Differences in HLA Mismatch Potential Among Kidney Registrations
A. Robinson¹, K. Lindblad¹, D. Stewart¹, J. Kim², V. Casingal³, P. Lalli³, J. Lunz⁴, C. Murphey⁵, M. Pavlakis⁶
¹UNOS, Richmond, VA, ²Surgery, Keck Medicine of USC, Los Angeles, CA, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Southwest Immunodiagnostics, Inc., San Antonio, TX, ⁶Beth Israel Deaconess Med Ctr, Boston, MA
*Purpose: HLA matched kidneys are associated with better long-term post-transplant graft survival. However, prioritizing patients well-matched with an available donor has historically resulted in disparities…
2022 American Transplant Congress
XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations
G. Codispodo, J. Hedvat, D. Salerno, N. Lange
Pharmacy, NewYork-Presbyterian Hospital, New York, NY
*Purpose: At our center, the use of de novo Envarsus XR® (extended-release [XR] tacrolimus) dosed at 0.12 mg/kg is standard of care in adult kidney…
2022 American Transplant Congress
Baseline Levels and Early Post-Transplant Kinetics of Donor-Derived Cell-Free DNA Following Liver Transplantation
S. Florman¹, D. Axelrod², J. Miles³, E. Vaskova³, D. Kilam³, K. Dhanireddy⁴, V. Subramanian⁴
¹Mount Sinai Medical Center, New York, NY, ²University of Iowa, Iowa City, IA, ³CareDx, South San Francisco, CA, ⁴Tampa General Hospital, Tampa, FL
*Purpose: Non-invasive biomarkers in liver transplant (LT) are needed to improve detection of allograft injury in routine surveillance and during immunosuppression modulation, prior to the…
2022 American Transplant Congress
Single Center Early Experience with Urinary Multi Biomarker – Qsant
Y. A. Qazi, W. Mon, C. Choi, M. Smogorzewski
Keck Medical Center at USC, Los Angeles, CA
*Purpose: QSant™, an urine-based test was recently introduced for detection of kidney transplant rejection. The test is being utilized at our center to help identify…